ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO741

Impact of Type 2 Diabetes Mellitus (T2DM) with or without Diabetic Nephropathy (DN) on Long-Term Outcomes in ESKD Patients Initiated on Dialysis

Session Information

Category: Diabetes

  • 502 Diabetes Mellitus and Obesity: Clinical


  • Lim, Wai Hon, Sir Charles Gairdner Hospital, Perth, New South Wales, Australia
  • Johnson, David W., Princess Alexandra Hospital, Brisbane, Queensland, Australia
  • Polkinghorne, Kevan, Monash Medical Centre and Monash University, Melbourne, Victoria, Australia
  • Hawley, Carmel M., Princess Alexandra Hospital, Brisbane, Queensland, Australia
  • Lok, Charmaine E., Toronto General Hospital, Toronto, Ontario, Canada
  • Wong, Germaine, None, Auambie, New South Wales, Australia

DN is the most common cause of ESKD among patients with T2DM, however there is growing evidence that T2DM patients with non-DN as a cause of ESKD form a distinct clinical entity with differential prognostic significance


All incident ESKD patients initiated on hemodialysis/peritoneal dialysis in Australia and New Zealand between 1980-2014 were included, using data from the ANZDATA Registry. The association between diabetes status at dialysis initiation (i.e. no diabetes, T2DM+DN or T2DM+non-DN) and mortality were examined using Cox regression and competing risk analyses, with transplantation censored or considered as competing risk, respectively


Of 56,552 incident dialysis patients followed for a median of 2.5 years, 15,829 (28%) and 4993 (9%) had T2DM+DN and T2DM+non-DN, respectively. Patients with T2DM were significantly older and a greater proportion had vascular comorbidities. Compared to patients with no diabetes, the adjusted HR (95%CI) for mortality in those with T2DM+DN and T2DM+non-DN were 1.39 (1.35-1.43) and 1.24 (1.29-1.29) in the Cox regression model, and the adjusted subdistribution HR were 1.52 (1.47-1.56) and 1.32 (1.27-1.38), respectively in the competing risk model. There was a significant interaction (p<0.001) between age and diabetes status, with the hazard for mortality greater in younger compared to older patients. Cardiovascular disease as a cause of mortality was more common in patients with T2DM compared to no diabetes (43% vs. 34%, p<0.001). Kaplan Meier survival curves for mortality stratified by age categories are shown below


Younger ESKD diabetic patients with or without DN experienced substantially poorer survival compared to non-diabetic patients. A vigilant approach to CVD prevention and monitoring is critical to improve clinical outcomes in diabetic patients with ESKD